Blackstone commits $250m to back new CAR T-cell therapies

Blackstone Life Sciences is investing $250 million toward developing CAR T-cell therapies for immuno-oncology and autoimmune diseases, forming a new company structured to handle clinical-stage cell therapies along with Intellia Therapeutics and Germany's Cellex Cell Professionals GmBH.

Officials said the new company will combine GEMoaB’s clinical-stage universal CAR-T platforms with Intellia’s allogeneic cell platform and CRISPR cell engineering.

The headquarters for the new company will be in life sciences hub Cambridge, Massachusetts, where Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.

Monthly subscriptions and discounted corporate plans for up to 100 members also available.

Related Articles

Back to top button

Start Your Days in the Know


Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!